Drugs / VE202
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05370885 | May 2023 → Aug 2025 | ulcerative colitis | Vedanta Biosciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VE202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370885 ↗ |
| Modality | Other / unclassified | “VE202 is a rationally defined, live biotherapeutic product for oral administration.” NCT05370885 ↗ |
| Route | Oral | “VE202 is a rationally defined, live biotherapeutic product for oral administration.” NCT05370885 ↗ |